Nearly five years after COVID-19 first upended daily life, the virus continues to evolve. The latest variant gaining attention is called Stratus — a name already making its way through news headlines, social media chatter, and public health briefings. First flagged in multiple U.S. states and several countries in late 2024, Stratus is now showing steady growth in reported cases across the globe.

What makes it different? Scientists say Stratus belongs to the Omicron family, but carries a distinct set of mutations that may affect how it spreads and the symptoms it causes. While early data is still emerging, its trajectory has many experts urging caution without panic.

Stratus (officially XFG) popped up on researchers’ radar in early 2025 as a genetic recombination of two prior COVID-19 strains—LF.7 and LP.8.1.2. By late spring, it accounted for nearly 23% of global cases, and hovered at around 14% in the US. In England, its rapid climb—from 10% to 40% prevalence in mere weeks—warranted media nicknames like “Frankenstein variant” and set off alarm bells about just how fast it can spread. The World Health Organization currently lists Stratus as a variant under monitoring, citing its concerning immune-escape mutations but noting the overall public health risk remains low for now.

Also Read: Ozempic Users Found To Age Back By More Than 3 Years, Finds New Trial; Peer Review Pending

How Stratus Is Spreading?

Stratus’ dominance across regions stems from its transmissibility, not its severity. Four key mutations in the spike protein may help it evade immunity—whether from past infection or vaccination—but there’s no sign yet that it causes more severe disease.

Data from the U.S. Centers for Disease Control and Prevention (CDC) shows Stratus now accounts for a growing percentage of new COVID cases nationwide, particularly in urban centers with high travel activity. Similar trends are being reported in parts of Europe, Asia, and Australia.

Unlike earlier variants that surged sharply, Stratus appears to be building momentum more gradually — but steadily. This slower curve may allow it to spread under the radar for longer, especially in areas where testing and genomic sequencing have scaled back since the height of the pandemic.

What Are Stratus Symptoms You Should Know

If you’ve been keeping track, sore throats—and not just any sore throat—have become Stratus’ odd signature. People describe it as scratchy or raspy tones, easily mistaken for allergies or seasonal laryngitis. According to early clinical reports, the most common Stratus symptoms include:

• Persistent sore throat or hoarseness
• Headaches that last several days
• Nasal congestion and mild fever
• Fatigue that lingers beyond the acute phase

Some patients also report changes in smell or taste, but less frequently than with earlier variants. Shortness of breath and chest discomfort remain uncommon in vaccinated individuals but can occur in higher-risk groups.

Doctors stress that the full symptom spectrum may become clearer as more data is collected over the coming months.

COVID now spreads faster than before. According to updated medical data, incubation with Omicron-like variants—including Stratus—is often around 3 to 4 days—shorter than earlier strains’ 5–7 days. That means the usual advice is still relevant:

• If symptoms begin, test early—but not too early, since antigen kits may fail at onset.
• If negative, test again in 24–48 hours if symptoms persist.
• Most adults can end isolation after 5 to 7 days, provided symptoms are improving and any fever has resolved 24 hours without medication.

Expired or faulty tests? Double-check the control line on your test. If it doesn’t appear, the kit may be invalid—even if unused

Why New Variants Keep Appearing?

Viruses mutate — it’s part of their survival strategy. Each time SARS-CoV-2 infects someone, it makes copies of itself. Occasionally, those copies contain genetic changes that give the virus an advantage, such as spreading more efficiently or dodging parts of our immune response.

For Stratus, researchers are still analyzing whether its mutations make it more transmissible or better at evading immunity from vaccines or past infections. What’s clear is that population immunity, while strong, is not absolute — especially as antibody levels naturally wane over time.

Current COVID vaccines, including updated boosters targeting recent Omicron strains, are still expected to offer protection against severe illness from Stratus. However, breakthrough infections are possible, particularly in people who haven’t had a booster in the last 6–12 months.

Public health agencies continue to recommend boosters for older adults, people with weakened immune systems, and those working in high-exposure settings. Whether a Stratus-specific vaccine update will be needed remains to be seen.

Is Preventing Spread in 2025 A Reality?

We’re no longer in the emergency stage of the pandemic, but familiar prevention strategies still matter:

• Staying home if you’re sick
• Masking in crowded indoor spaces during surges
• Testing before visiting vulnerable individuals
• Keeping up to date on vaccinations

With reduced restrictions and increased global mobility, even moderate increases in transmission can ripple quickly through communities — especially during cold and flu season.

Researchers are tracking whether Stratus leads to more reinfections, if its symptoms last longer, and whether it’s linked to post-COVID complications like long COVID. Hospitals are monitoring for any shifts in admission patterns, particularly among children and older adults.

There’s also a focus on transparency: experts say real-time sharing of data across countries is essential for staying ahead of variant-driven waves.

Stratus isn’t dramatically different—no skyrocketed hospitalizations, no alarming new symptom profiles. But it does remind us that SARS-CoV-2 is still evolving, still engaging our resilience and still requiring vigilance.

You don’t need to panic. But staying informed, testing responsibly, masking when needed, and keeping vaccinations up to date that’s how we stay ahead of the next wave.

The Central Drugs Standard Control Organisation (CDSCO) has now launched a nationwide crackdown on unapproved Fixed Dose Combination (FDCs) after 90 combination medicines that were being sold without mandatory central approval were busted last week.

CDSCO, India's apex drug regulatory body in the country, made the shocking discovery after scrutinizing drug samples uploaded on the SUGAM portal, the government’s online system for drug testing data.

Several of these samples were found to fall under the ‘new drug’ category but lacked approval from the central authority. As a result, the CDSCO wrote a letter to all states and union territory drug controllers, asking them to investigate manufacturers and marketers of these FDCs.

The letter reads: "The SUGAM lab testing data for the year 2025, a large number of drug samples (FDCs) are detected as unapproved and fall under the category of 'New Drug'. No new drug shall be manufactured for sale unless it is approved by the Licensing Authority 'as defined in Rule 3 of New Drugs and Clinical Trial Rules, 2019, Further, as per Rule 80 of New Drugs & Clinical Trial Rules 2019, a person who intends to manufacture new drug in the form of API or Pharmaceuticals formulation, as the case may be, for sale or distribution, shall make an application for grant of permission to the Central Licensing Authority in Form CT-21 along with a fee as specified in Sixth Schedule."

"The presence of unapproved drugs in the supply chain is a matter of serious concern, posing potential risks to public health and safety. It also indicates non- compliance with the provisions of the Drugs and Cosmetics Act, 1940, and rules made thereunder.

"Accordingly, please initiate appropriate investigation and regulatory action against the concerned manufacturers, marketers, and other stakeholders, as deemed fit. Kindly ensure strict monitoring and enforcement to prevent manufacture, sale, and distribution of such unapproved drugs," the letter states, on appropriate action against the sale and distribution of unapproved drugs.

FDCs are drugs that contain two or more active ingredients in a single formulation. The CDSCO has asked states to investigate and submit reports on the action taken at the earliest.

What Made It To The Unapproved List Of FDCs?

Cough And Cold Medicines

Cough and cold combination medicines have formed the single largest group. At least 14 to 16 entries show combination of ingredients found in everyday pharmacy shelves: dextromethorphan, ambroxol, guaiphenesin, chlorpheniramine, phenylephrine, terbutaline, and menthol in various permutations.

Several of these are sold as flavoured syrups for children. Budesonide-levosalbutamol inhalation suspension that is used for asthma and chronic obstructive pulmonary disease, too features in the list.

Nutritional Supplements

The next group is of the vitamins, minerals and other nutritional supplement which has roughly 18 to 20 entries. They include:

• Multivitamin capsules
• Iron-folic acid syrups
• Calcium-vitamin D3-K2 combinations
• Abapentin-methylcobalamin preparation

This group has accounted for at least 10 entries, which include antifungal creams that could lead to potential misuse and skin damage when sold without prescriptions.

Anti-Diabetic Medicines

This has accounted for six entries, and the combination includes:

• Glimepiride paired with metformin or pioglitazone

What Is India's Rule For FDCs?

Under India's New Drugs and Clinical Trial Rules of 2019, any FDC is treated as a new drug and must have the central government's approval before it could be manufactured and sold. The regulator's letter noted that there were presence of unapproved drugs in the supply chain that could pose risks to public health. This also amounts to a violation of the Drugs and Cosmetics Act, 1940.

“The presence of unapproved drugs in the supply chain is a matter of serious concern, posing potential risks to public health and safety. It also indicates non- compliance with the provisions of the Drugs and Cosmetics Act, 1940, and Rules made thereunder," it said.

DCGI urged states and UTs "to examine the unapproved FDCs in generic name as mentioned in the attached annexure". This is done to check whether any approval has been granted by the local office. "Accordingly, please initiate appropriate investigation and regulatory action against the concerned manufacturers, marketers, and other stakeholders, as deemed fit. Kindly ensure strict monitoring and enforcement to prevent the manufacture, sale, and distribution of such unapproved drugs," the letter noted.

Breakbone Fever, also known as dengue, is a mosquito-borne disease that is once again on the rise, with the U.S. Centers for Disease Control and Prevention issuing a travel alert across 17 Countries.

The federal agency flagged 'Level 1' risk for breakbone fever, calling for practicing usual precautions. It stated a higher-than-expected number of cases and urged people planning to travel to countries with an uptick in cases to be aware of the risk.

The CDC alert issued on March 23 identified 17 countries reporting an increased number of cases of dengue. These include: Afghanistan, Bangladesh, Bolivia, Colombia, Cook Islands, Cuba, Guyana, Maldives, Mali, Mauritania, New Caledonia, Pakistan, Samoa, Sudan, Timor-Leste, Vietnam, and the United States territories of American Samoa, Puerto Rico, and the US Virgin Islands, where local transmission is already common.

In 2026, the US reported a total of 496 dengue cases to date, and the vast majority of these cases were reported among people who contracted the illness while traveling abroad.

The CDC advised travelers to risk areas to prevent mosquito bites by

• using an EPA-registered insect repellent,
• wearing long-sleeved shirts
• long pants when outdoors,
• sleeping in an air-conditioned room or a room with window screens.

What Is Dengue? Why Is It Called Breakbone Fever

Dengue is a disease caused by a virus spread through mosquito bites. It is transmitted through infected mosquitoes, primarily the species Aedes aegypti.

The breakbone fever is caused by an infection with any of four different dengue viruses. These include:

• Dengue virus type 1 (DENV-1 or DEN-1)
• Dengue virus type 2 (DENV-2 or DEN-2)
• Dengue virus type 3 (DENV-3 or DEN-3)
• Dengue virus type 4 (DENV-4 or DEN-4)

Common Symptoms of the dengue are:

• Sudden onset of high-grade fever.
• Intense headache
• Severe muscle, joint, or bone pain.
• Skin Rash that often appears 2–5 days after the fever starts
• Nausea and Vomiting
• Minor bleeding
• Fatigue.

The disease can take up to 2 weeks to develop, with illness generally lasting less than a week.

However, it can quickly become severe within a few hours, usually requiring hospitalization.

In severe cases, health effects can include hemorrhage (uncontrolled bleeding), shock (seriously low blood pressure), organ failure, and death.

Breakbone Fever: Global Burden

According to the World Health Organization (WHO), about half of the world's population is now at risk of dengue.

It estimates that:

• About 390 million dengue infections occur annually worldwide
• Nearly 100 million people develop symptoms each year

The two main authorized vaccines in the world against dengue are Dengvaxia and Qdenga.

These vaccines are designed to protect against all four serotypes of the virus, with a focus on reducing severe disease and hospitalizations.

In addition, the Butantan-DV vaccine developed by the Butantan Institute in São Paulo has shown potential to be over 80 percent effective in preventing the risk of severe disease for up to five years. It also offers broader protection against all four dengue serotypes.

Sonia Gandhi, Congress Parliamentary Party chairperson, is under treatment for systemic infection, said the doctors treating her at the private hospital in Delhi, today.

The Rajya Sabha MP was admitted to the Sir Ganga Ram Hospital on March 24, 2026. As per initial reports, she was feeling unwell due to the change in weather and has been put under observation.

"Sonia Gandhi has been admitted to Sir Ganga Ram Hospital on 24th March night for fever. As per Dr. Ajay Swaroop, Chairman of SGRH, she is undergoing treatment with antibiotics for systemic infection,” the hospital said in a statement.

She "is showing response to treatment", it added.

Earlier, the hospital noted that the doctors are conducting further investigations to check for possible infection in the stomach and urinary tract.

What Is A Systemic Infection?

Systemic infection occurs in the bloodstream and affects the entire body, rather than a single organ or body part.

It occurs when pathogens like bacteria, viruses, or fungi enter the bloodstream and travel to multiple organs and tissues.

These infections can be life-threatening and common symptoms include:

• high fever,
• fatigue,
• rapid heart rate,
• confusion.

Earlier this year, in January, Sonia Gandhi was admitted to Sir Ganga Ram Hospital after she suffered respiratory discomfort.

Also Read: COVID Variant BA.3.2 Spreads To 23 Countries: Is The Variant Under Monitoring A Cause Of Worry?

Did Delhi Pollution Make Sonia Gandhi Sick?

Due to an increase in population during the peak winter season in Delhi, the 79-year-old Parliamentarian had been regular with hospital visits and check-ups. Hospital source, while speaking to the news agency PTI, said that "it is a routine admission".

According to reports, she had complained of some respiratory discomfort. Once her medical examination was done, it was found that "her bronchial asthma had been mildly exacerbated", confirmed Dr. Swaroop.

A hospital source told PTI that this is due to the combined effects of cold weather and pollution.

As a precautionary measure, she was admitted to the hospital for further observation and treatment. The physicians who were treating her made a decision on her discharge based on her clinical progress.

Sonia Gandhi's Health History

On June 7, 2025, she was admitted to the Indira Gandhi Medical College and Hospital (IGMC) in Shimla for a routine medical check-up. She was also later discharged after her medical examination.

As per Naresh Chauhan, Principal Advisor (Media) to the Himachal Pradesh Chief Minister, she was brought in due to minor health concerns. However, he said that after being put under observation by doctors to assess her condition, she was stable.

Dr. Aman Chauhan, Deputy Medical Superintendent at IGMC, said, "Her blood pressure was slightly on the higher side, but there is nothing serious. No additional tests were conducted; only routine investigations were carried out. She was not given any special medical advice because everything was perfectly fine."

In the same month, on June 15, she was admitted to Sir Ganga Ram Hospital again under the Department of Surgical Gastroenterology for a stomach-related issue. Before that, she was again in the Delhi hospital on June 9 for a medical check-up.